History
ALETTA since 2018 — from real-world evidence to everyday wellbeing
ALETTA began as a digital-health platform for patient-reported outcomes and real-world data, owned and developed by MYCB1 Group B.V. Since August 2025 ALETTA is owned by Ernexo Holding B.V., which leads its next generation: a lifestyle and wellbeing app.
2018
Foundations.
ALETTA is conceived by Ernesto Diringuer within MYCB1 to help track patients' health-related quality of life, with a patient app, a doctor dashboard and a pharmacy portal. Owner and developer: MYCB1 Group B.V.
October 2020
Trademark filing.
ALETTA is filed at the Benelux Office for Intellectual Property, followed by EU and international registrations.
May 2022
ALETTA 1.0 in practice.
Patients report wellbeing and side effects through the ALETTA app, and doctors and researchers use it to collect real-world data. Outcomes of ALETTA 1.0 in a real-world setting are presented at the KNMP PRISMA Symposium 2022.
April 2023
Germany.
ALETTA is positioned as MYCB1's real-world evidence platform as part of its German market launch.
May 2023
ALETTA 2.0 and Scandinavia.
An exclusive distribution agreement is signed covering the introduction of ALETTA 2.0 in Scandinavian markets.
February 2024
ALETTA on the App Store.
The ALETTA app is published on the Apple App Store (Medical category) as a data-sharing and communication platform for patients and healthcare professionals, with regular updates through 2024.
August 2025
New owner.
The ALETTA brand and trademarks are assigned from MYCB1 Group B.V. to Ernexo Holding B.V., which now owns ALETTA and leads all new development.
2026
The next generation.
Ernexo Holding B.V. is developing the new ALETTA app: one platform for AI-powered lifestyle and health companions, with secure chat, for iOS and Android.
Referenced in
- KNMP PRISMA Symposium 2022
- Bedrocan (2022, 2023)
- DanCann Pharma (2023)
- Apple App Store (2024)